Cargando…
Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients
PURPOSE: Immune checkpoint inhibitor (ICI)-induced hepatitis belongs to the frequently occurring immune-related adverse events (irAEs), particularly with the combination therapy involving ipilimumab and nivolumab. However, predisposing factors predicting the occurrence of ICI-induced hepatitis are b...
Autores principales: | Purde, Mette-Triin, Niederer, Rebekka, Wagner, Nikolaus B., Diem, Stefan, Berner, Fiamma, Hasan Ali, Omar, Hillmann, Dorothea, Bergamin, Irina, Joerger, Markus, Risch, Martin, Niederhauser, Christoph, Lenz, Tobias L., Früh, Martin, Risch, Lorenz, Semela, David, Flatz, Lukas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8881258/ https://www.ncbi.nlm.nih.gov/pubmed/34874490 http://dx.doi.org/10.1007/s00432-021-03870-6 |
Ejemplares similares
-
Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients
por: Fässler, Mirjam, et al.
Publicado: (2019) -
Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment
por: Diem, Stefan, et al.
Publicado: (2018) -
Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival
por: Berner, Fiamma, et al.
Publicado: (2021) -
C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer
por: Klümper, Niklas, et al.
Publicado: (2022) -
Local tumor microbial signatures and response to checkpoint blockade in non-small cell lung cancer
por: Boesch, Maximilian, et al.
Publicado: (2021)